Endocrine manifestations in adults with 22q11.2 deletion syndrome: a retrospective single-center cohort study
Open Access
- 3 February 2024
- journal article
- research article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 47 (7) , 1827-1836
Abstract
Introduction and objective: Patients with the 22q11.2 deletion syndrome (22q11DS) frequently display cardiological and psychiatric diseases, but are also at increased risk for endocrine manifestations. The aim of this study was to evaluate the screening, prevalence, and management of hypoparathyroidism and thyroid disease in patients with 22q11DS, to evaluate the metabolic profile, and to compare these results with current literature and guidelines. Design: We performed a retrospective study of patients with genetically confirmed 22q11DS, followed at the center for human genetics of the University Hospitals Leuven, resulting in a cohort of 75 patients. Medical history, medication, and laboratory results concerning hypoparathyroidism, thyroid dysfunction, and the metabolic profile were collected. Results: Of the total cohort, 26 patients (35%) had at least one hypocalcaemic episode. During hypocalcaemia, parathyroid hormone (PTH) was measured in only 12 patients with 11 having normal or low PTH, confirming a diagnosis of hypoparathyroidism. Recurrent episodes of hypocalcaemia occurred in seventeen patients (23%). Adherence to the guidelines was low, with 13% of patients having a yearly serum calcium evaluation, 12% receiving daily calcium supplements, and 20% receiving non-active vitamin D. Hypothyroidism was present in 31 patients (44%) and hyperthyroidism in 6 patients (8%). Information on body mass index (BMI) was available in 52 patients (69%), of which 38% were obese (BMI ≥ 30 kg/m2). Conclusion: Hypoparathyroidism, hypothyroidism, and obesity are common endocrine manifestations in patients with 22q11DS but are probably underdiagnosed and undertreated, indicating the need for multidisciplinary follow-up including an endocrinologist.Keywords
Funding Information
- NIH Blueprint for Neuroscience Research (grant 1U01MH101722-01, grant 1U01MH101722-01)
This publication has 37 references indexed in Scilit:
- Prevalence of hypocalcaemia and its associated features in 22q11·2 deletion syndromeClinical Endocrinology, 2014
- Syndrome‐specific growth charts for 22q11.2 deletion syndrome in Caucasian childrenAmerican Journal of Medical Genetics Part A, 2012
- Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome)Medicine, 2011
- Thyroid function and morphology in subjects with microdeletion of chromosome 22q11 (del(22)(q11))Clinical Endocrinology, 2010
- Thyroid gland and carotid artery anomalies in 22q11.2 deletion syndromesThe Laryngoscope, 2009
- Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromesThe Lancet, 2007
- Endocrine Manifestations of Chromosome 22q11.2 Microdeletion SyndromeHormone Research in Paediatrics, 2005
- Syndrome de délétion 22q11 et maladie de Basedow. À propos de trois observations pédiatriquesArchives de Pédiatrie, 2004
- Hypoparathyroidism and 22q11 deletion syndromeArchives of Disease in Childhood, 2003
- The spectrum of the DiGeorge syndromeThe Journal of Pediatrics, 1979